Dr. Eyre on BTK Inhibitors in Combination With Venetoclax for MCL

Video

Toby Eyre, MBChB, MRCP, consultant hematologist at Oxford University Hospitals NHS Trust, discusses the potential for BTK inhibitors to be used in combination with venetoclax for mantle cell lymphoma.

Toby Eyre, MCBhB, MRCP, consultant hematologist at Oxford University Hospitals NHS Trust, discusses the potential for BTK inhibitors to be used in combination with venetoclax (Venclexta) for the treatment of patients with mantle cell lymphoma (MCL).

Venetoclax has been extremely effective in patients with chronic lymphocytic leukemia, and it is now being tested with BTK inhibitors in that space. The same thing is starting to happen in MCL, Eyre says. A previous phase I study showed an overall response rate of 75% and a progression-free survival of just under 14 months with venetoclax. Interestingly, similar data has been seen with ibrutinib (Imbruvica). Recent data was published looking at the combination in a small number of patients and it showed efficacy, particularly in terms of complete response rates and minimal residual disease—negativity. The natural next step, Eyre says, is to look at this combination further.

It remains to be seen what the tolerability will be for this combination. Venetoclax and ibrutinib have some overlapping toxicities like diarrhea, cytopenia, and neutropenia.

Related Videos
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH
Neil D. Gross, MD, FACS
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center